Two newly identified, overlapping (1 bp) glucocorticoid response elements (GREs) at Ϫ759 and Ϫ773 bp in the promoter of the rat phenylethanolamine N-methyltransferase (PNMT; EC 2.1.1.28) gene are primarily responsible for its glucocorticoid sensitivity, rather than the originally identified Ϫ533-bp GRE. A dose-dependent increase in PNMT promoter activity was observed in RS1 cells transfected with a wild-type PNMT promoter-luciferase reporter gene construct and treated with dexamethasone (maximum activation at 0.1 M). The type II glucocorticoid receptor antagonist RU38486 (10 M) fully inhibited dexamethasone (1 M) activation of the PNMT promoter, consistent with classical glucocorticoid receptors mediating corticosteroid-stimulated transcriptional activity. Relative IC 50 values from gel mobility shift competition assays showed that the Ϫ759-bp GRE has a 2-fold greater affinity for the glucocorticoid receptor than the Ϫ773-bp GRE. Site-directed mutation of the Ϫ533-, Ϫ759-, and Ϫ773-bp GREs alone or in tandem demonstrated that the Ϫ759-bp GRE was also functionally more important, but both the Ϫ759-and Ϫ773-bp GREs are required for maximum glucocorticoid responses. Moreover, the Ϫ533-bp GRE, rather than increasing glucocorticoid sensitivity of the promoter, may limit corticosteroid responsiveness mediated via the Ϫ759-and Ϫ773-bp GREs. Finally, the glucocorticoid receptor bound to the Ϫ759-and Ϫ773-bp GREs interacts cooperatively with Egr-1 and/or AP-2 to stimulate PNMT promoter activity in RS1 cells treated with dexamethasone. In contrast, glucocorticoid receptors bound to the Ϫ533-bp GRE only seem to participate in synergistic activation of the PNMT promoter through interaction with activator protein 2.
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Glucocorticoids are critical regulators of phenylethanolamine N-methyltransferase (PNMT; EC 2.1.1.28), the final enzyme in epinephrine biosynthesis, exerting both transcriptional and post-transcriptional influences. In vivo studies in rats have shown that depletion of corticosteroids by hypophysectomy decreases PNMT mRNA and enzyme expression (Evinger et al., 1992; Wong et al., 1992a Wong et al., , 1996 Evinger, 1998) . These changes can be reversed by administration of adrenocorticotropin, which stimulates endogenous glucocorticoid production, or direct corticosteroid replacement by administration of the synthetic glucocorticoid dexamethasone. Changes in PNMT enzyme are a consequence of alterations in both gene transcription and proteolytic degradation (Berenbeim et al., 1979; Wong et al., 1985) . In terms of the latter, corticosteroids sustain methionine adenosyltransferase and S-adenosylhomocysteine hydrolase, the metabolic enzymes responsible for maintaining the cosubstrate and methyl donor, S-adenosylmethionine. Sufficient AdoMet is thereby provided for PNMT enzymatic activity; in addition, however, the binding of AdoMet to PNMT protects it against proteolysis.
When intact rats are administered either dexamethasone or the glucocorticoid agonist RU28362, PNMT mRNA levels rise markedly (Wong et al., 1992b) because of increased gene transcription. Although it remains unclear whether glucocorticoids are essential for PNMT transcriptional activity, glucocorticoid receptor-deficient mice do not express adrenal medullary PNMT although chromaffin cells are otherwise ostensibly normal (Schmid et al., 1995; Finotto et al., 1999) .
Glucocorticoid-induced transcriptional changes are mediated through glucocorticoid response elements (GREs) in the proximal 5Ј flanking sequences of the PNMT gene promoter. At least one putative GRE has been identified for every species-specific PNMT gene, including human (Baetge et al., 1988; Kaneda et al., 1988) , cow (Baetge et al., 1986; Batter et al., 1988) , rat (Ross et al., 1990) , and mouse (Morita et al., 1992) . In the case of the rat PNMT gene, a GRE was identified at Ϫ533 bp when the gene was first cloned (Ross et al., 1990) . Although this GRE seemed to be functional, its responsiveness to glucocorticoid activation seems both variable and weak. At best, glucocorticoid treatment (1 M dexameth-asone) elicits no greater than a 2-fold induction of the PNMT promoter as demonstrated through transient transfection assays with PNMT promoter-luciferase reporter gene constructs or changes in PNMT mRNA measured by ribonuclease protection assays . However, glucocorticoid-activated glucocorticoid receptors (GR), bound to the Ϫ533-bp GRE, seem to interact cooperatively with other transcriptional activators bound to their cognate recognition sites [e.g., the immediate early gene transcription factor Egr-1 (Ebert et al., 1994) and the developmental transcription factor AP-2 ] to synergistically stimulate the PNMT promoter.
This study is the first to definitively identify the primary GREs mediating the glucocorticoid responsiveness of the rat PNMT gene. The sites at Ϫ759 and Ϫ773 bp have been characterized extensively and their functionality has been established. Glucocorticoid receptors bound to the GREs are further shown to participate in cooperative interactions with two other PNMT transcriptional activators, Egr-1 and AP-2, which is probably important for their biological activity. Finally, it is demonstrated that glucocorticoid receptor activation of these GREs and/or their synergistic interactions with Egr-1 and AP-2 also stimulates the endogenous PNMT gene in a manner consistent with their stimulation of the PNMT promoter, whereas the original GRE (Ϫ533 bp) only shows apparent synergism with AP-2.
Materials and Methods
Plasmids and Oligonucleotides. The wild-type construct pGL3RP893 was generated by subcloning the proximal 863 bp of proximal rat PNMT promoter sequences into the plasmid pGL3Basic (Pharmacia-Upjohn, Kalamazoo, MI). Verification of the promoter fragment by DNA sequence analysis (Her et al., 1999) showed that the insert was 893 bp in length, rather than 863 bp as identified originally (Ross et al., 1990) . The difference arises in GC-rich regions where G and C residue determination may be difficult and is consistent with a recent report on this proximal extent of PNMT promoter (Evinger, 1998) . Hence, the full-length construct was redesignated pGL3RP893.
Nested deletion constructs pGL3RP849, pGL3RP798, pGL3RP745, pGL3RP665, and pGL3RP557 were produced from the wild-type construct pGL3RP893 by 5Ј exonuclease digestion, followed by religation. Constructs with site-directed mutations in the GREs were also developed. The wild-type construct pGL3RP790 and mutant construct pGL3RP790mut533 were generated by subcloning the XhoI-HindIII restriction fragments from pRP893LUC and pRP893mutGRE1LUC into the corresponding restriction sites of the pGL3Basic vector upstream of the luciferase reporter gene. The remaining mutant constructs, pGL3RP790mut759, pGL3RP790mut773, and pGL3RP790mut759/773, were produced from pGL3RP790 using the polymerase chain reaction as described below.
For gel mobility shift assays, protein-DNA complexes were formed using the wild-type 40-bp oligonucleotide GRE773/759. Competitor oligonucleotides included unlabeled GRE773/759, GRE773, GRE759, and palGRE, with nucleotide sequences as follows: 5ЈGTACCAAG-AATGTGTTCTGCACTCTCTGTTCTTACACGAG3Ј (Ϫ790 3 Ϫ751, GRE773/759); 5ЈGTACCAAGAATGTGTTCTGCA3Ј (Ϫ790 3 Ϫ770, GRE773); 5ЈTTCTGCACTCTCTGTTCTTAC3Ј (Ϫ776 3 Ϫ756, GRE759); and 5ЈAGAGGATCTGTACAGGATGTTCTAGAT [palindromic (Scheidereit and Beato, 1984) or palGRE].
Egr-1 (Sukhatme et al., 1988) and AP-2 (Mitchell et al., 1987 ) expression and control constructs were kindly provided by Dr. Vikas Sukhatme (Harvard Medical School, Boston, MA) and Dr. Trevor Williams (Yale University, New Haven, CT) respectively. Transient Transfection Assays. Transient transfection assays were executed as described previously (Her et al., 1999; Tai et al., 2001) in the rat pheochromocytoma-derived RS1 cells (Ebert et al., 1994) . Briefly, cells were maintained in Dulbecco's modified Eagle's medium supplemented with 5% bovine calf serum, 5% equine serum (Hyclone, Logan, UT), 20 units/ml of hygromycin B (Calbiochem, La Jolla, CA), and 50 g/ml gentamicin sulfate (U.S. Biochemicals Corp., Cleveland, OH) at 37°C in an atmosphere of 5% CO 2 /95% air. All sera were charcoal-treated to remove endogenous glucocorticoids.
For transfection, cells were plated into 24-well culture dishes (2 ϫ 10 5 cells/well) and held at 37°C and 5% CO 2 /95% air overnight. Transfection was then performed using Superfect (QIAGEN, Inc., Valencia, CA) or polyethylenimine (Boussif et al., 1995) including 0.5 to 1.0 g of wild-type or mutant PNMT promoter-luciferase reporter gene construct, 0 to 1.5 g of expression or null construct, pCMVEgr-1 or pCMVETTL (Gupta et al., 1991) and/or pSPRSV-AP-2 or pSPRSV-NN (Williams and Tjian, 1991) , and 0.3 g of pRSV-LacZ normalization control construct. Total transfected DNA was adjusted to 3.0 g by making up the difference with the pGL3Basic plasmid vector. After transfection, cells were exchanged to culture medium and maintained an additional 24 h. To examine the effects of dexamethasone and the antiglucocorticoid RU38486 (Roussel-UCLAF, Romaineville, France), transfected cells were exposed to dexamethasone (0-10 M; Sigma Chemical, St. Louis, MO) for 6 h or pretreated with the antagonist for 1 h (0-10 M), followed by 1 M dexamethasone treatment for 6 h. The cells were then collected, lysed, and assayed for luciferase and ␤-galactosidase as described below.
Luciferase and ␤-Galactosidase Assays. After removal of the culture medium, the cells were washed twice with phosphate-buffered saline and then lysed in 100 l of lysis buffer (Promega, Inc., Madison, WI). Cellular debris was removed by centrifugation at 800g and luciferase activity measured in 20 l of cell lysate appropriately diluted to yield luciferase activity within the linear range as defined with purified luciferase using the Luciferase Assay System described previously (Ebert et al., 1994) . Protein was determined by the method of Bradford (1976) and luciferase activity was adjusted for protein concentration. To correct for variation in transfection efficiency, ␤-galactosidase activity was also determined (Ebert et al., 1994) and luciferase activity expressed relative to ␤-galactosidase generated from the pRSV-LacZ control construct. As appropriate, the ratio of luciferase/␤-galactosidase for the wild-type PNMT promoterluciferase reporter gene construct was set to unity, and the ratio of luciferase/␤-galactosidase for other constructs expressed relative to it. Alternatively, the ratio of luciferase/␤-galactosidase expressed by PNMT promoter-luciferase constructs, wild-type, truncated or mutant constructs, in the absence of dexamethasone, was set to unity, and values in the presence of dexamethasone expressed relative to these respective untreated controls. At least six replicates were included in each sample group and experiments repeated two to three times.
Site-Directed Mutagenesis. Site-directed mutation of the Ϫ759-and Ϫ773-bp GREs was performed by polymerase chain reaction as described previously using the following 40-bp mutagenic primers, spanning upstream sequences from Ϫ790 to Ϫ751 bp in the PNMT promoter (Her et al., 1999) : 5ЈGTACCAAGAATGTcaTCTGCAC-TCTCTGTTCTTACACGAG3Ј (mut773); 5ЈGTACCAAGAATGTGT-TCTGCACTCTCTcaTCTTACACGAG3Ј (mut759); and 5ЈGTACCAA-GAATGTcaTCTGCACTCTCTcaTCTTACACGAG3Ј (mut773/759).
Gel Mobility Shift Competition Assays. As described previously (Her et al., 1999) , protein-DNA complexes were generated using 1 ng of the wild-type oligonucleotide probe GRE773/759, endlabeled with [␥- 32 P]ATP and T 4 polynucleotide kinase (3 nM, specific activity ϭ 2.5 ϫ 10 8 dpm/g), and a truncated GR protein (Dr. Keith Yamamoto, University of California, San Francisco) (Freedman et al., 1988) in 20 l of binding buffer consisting of 25 mM HEPES buffer, pH 7.9, 50 mM KCl, and 0.05 mM EDTA. Complexes were competed by including unlabeled oligonucleotides ranging in concen-tration from 1 to 1000 ng. The amount of residual complex was then quantified from its autoradiographic signal by scanning densitometry using Image software, version 1.52 (National Institutes of Health), on a Power MacIntosh 7500 computer and a Hewlett Packard 6100C scanner. IC 50 values were determined by linear regression analysis of graphs of optical density units versus ln[competitor oligonucleotide concentration] and calculation of the x-intercept.
Statistical Analysis. Data are presented as the mean Ϯ S.E.M. with n ϭ 6 for each experimental group. Statistical significance between groups was determined by one-way analysis of variance followed by post hoc comparison using Student's t test. A p value Յ0.05 was considered statistically significant.
Results
Glucocorticoid Responsiveness of the PNMT Promoter. To examine the glucocorticoid responsiveness of the PNMT promoter, the proximal 893 bp of 5Ј promoter/regulatory sequences were subcloned into the plasmid pGL3Basic (Pharmacia-Upjohn, Kalamazoo, MI) upstream of the firefly luciferase reporter gene. When this wild-type construct (pGL3RP893) was transiently transfected into the PC-12-derived RS1 cells (Ebert et al., 1994) and the cells treated with 1 M dexamethasone, luciferase activity was induced ϳ6.0-fold, markedly higher than reported previously (Fig. 1) .
To identify the glucocorticoid responsive DNA sequences within the promoter, nested deletion mutant PNMT promoter-luciferase reporter gene constructs were generated by 5Ј exonuclease digestion. Transient transfection assays in the absence and presence of dexamethasone (1 M) showed that the DNA sequences lying between Ϫ745 and Ϫ798 bp were responsible for the marked glucocorticoid induction of the promoter (Fig. 1) . Two of three plasmid constructs (pGL3RP557 and pGL3RP665) harboring only the proximal Ϫ533-bp GRE (previously designated Ϫ513 bp) (Ross et al., 1990) did not show any apparent corticosteroid activation, whereas a third (pGL3RP745) showed a 2-fold stimulation of the PNMT promoter. In addition, sequences beyond Ϫ798 bp seemed to limit the glucocorticoid responsiveness of the PNMT promoter. Highest dexamethasone stimulation of PNMT promoter-driven luciferase activity occurred with the construct containing 798 bp of promoter sequence (pGL3RP798). Longer constructs expressed lesser amounts of luciferase; the full-length construct pGL3RP893 showed only a 6.0-fold induction by comparison to the 12.0-fold induction seen with the construct pGL3RP798.
Matching of the DNA sequences in the glucocorticoid sensitive region to the consensus glucocorticoid response element, 5ЈTAGAACANNNTCTTCT3Ј (Scheidereit and Beato, 1984) , using the Transfac database (version 3.2) identified two new GREs. Based on the highly conserved 3Ј hexanucleotide sequence of the consensus GRE, TGTTCT, the 3Ј termini of these GREs were fixed at Ϫ759 and Ϫ773 bp, with a 1-bp overlap of their 5Ј and 3Ј ends, respectively.
Effects of Dexamethasone and RU38486 on PNMT Promoter Activation. Because longer constructs seemed to contain sequences inhibiting full glucocorticoid responsiveness of the PNMT promoter, the construct pGL3RP790, which shows comparable dexamethasone sensitivity to pGL3RP798, was used in subsequent studies (data not shown). A dose-response curve was first executed for dexamethasone ( Fig. 2A) . When RS1 cells transfected with pGL3RP790 were treated with 0 to 10 M dexamethasone for 6 h, a dose-dependent rise in PNMT promoter-driven luciferase reporter gene expression was observed. Maximum stimulation of the promoter occurred at 0.100 M. No significant change in activation was observed when the dexamethasone concentration was increased to 1 M dexamethasone. However, luciferase activity decreased to levels equivalent to 0.01 M dexamethasone when corticosteroid levels were increased to 10 M.
Because dexamethasone is both a type I and type II GR receptor agonist, with greater preference for type I receptors, the effects of RU38486, a specific type II GR antagonist, was investigated. RS1 cells transfected with pGL3RP790 were pretreated with RU38486 (0-10 M) for 1 h, followed by treatment with 1 M dexamethasone for 6 h and PNMT promoter-driven luciferase expression determined. As shown in Fig. 2B , RU38486 inhibited the dexamethasone-mediated rise in luciferase. A significant reduction in dexamethasonestimulated PNMT promoter activity was apparent at 0.001 M, with complete inhibition at 10 M RU38486.
Glucocorticoid Receptor Binding to the Upstream GREs and Activation of the PNMT Promoter. The previous results are consistent with type II GRs mediating PNMT promoter transcriptional activation. To demonstrate the specificity of the GR and its relative binding affinity for the newly identified GRE target sequences, gel mobility shift competition assays were executed (Fig. 3) . Protein-DNA binding complex was formed between a 40-bp 32 P-labeled wild-type oligonucleotide spanning both the Ϫ759-and Ϫ773-bp GREs and 5 bp of 5Ј and 3Ј flanking sequence and a truncated GR protein (Dr. Keith Yamamoto, University California, San Francisco). The complex was competed with increasing amounts of unlabeled oligonucleotide (1-1000 ng), including the unlabeled 40-bp oligonucleotide and 21-bp oligonucleotides encoding the Ϫ759-bp, Ϫ773-bp, and palindromic GRE sequences (Fig. 3A) . All oligonucleotides interacted with the GR peptide as demonstrated by their displacement of the radiolabeled DNA (Fig. 3B) . The abun- (Fig. 3, B and C) . The palindromic GRE and the oligonucleotide harboring both upstream GREs had the highest affinity for the GR (relative IC 50 values: 11.0 and 8.7, respectively). The affinities of the Ϫ759-and Ϫ773-bp GREs for the GR were ϳ3.5 to 7.0-fold lower based on relative IC 50 values; the Ϫ759-bp GRE had ϳ2-fold higher affinity (relative IC 50 , 30.6) for the GR than the Ϫ773-bp GRE (relative IC 50 , 60.8). The slopes of the regression curves for each competition assay did not significantly change, confirming that the differences in x-intercepts (IC 50 ) were caused solely by affinity of the DNA sequences for the GR and not differences in receptor abundance as well.
To further examine the functionality of the Ϫ759-and Ϫ773-bp GREs, site-directed mutations were introduced into the various GREs as described under Materials and Methods to produce the single mutant constructs pGL3RP790mut533, pGL3RP790mut759, and pGL3RP790mut773; the double mutant construct pGL3R790mut773/759; and the triple mutant construct pGL3RP790mut533/759/773. The wild-type or mutant constructs were then transiently transfected into RS1 cells and PNMT promoter-driven luciferase activity was determined in the absence or presence of dexamethasone (1 M) (Fig. 4A) . When the Ϫ533-bp GRE was mutated, rather than a decrease, a Ն1.5-fold increase in dexamethasonestimulated PNMT promoter activation occurred at dexamethasone concentrations between 0.01 and 1 M. By contrast, mutation of either the Ϫ759 or Ϫ773-bp GRE markedly attenuated dexamethasone-stimulated PNMT promoter activity. However, when the Ϫ773-bp GRE was mutated, a dose-dependent increase in PNMT promoter-driven luciferase activity was still apparent, although maximum induction was only 3.1-fold (1 M dexamethasone). As observed with all GREs intact, 10 M dexamethasone stimulated the PNMT promoter less than 1 M dexamethasone. When the Fig. 2 . Effects of dexamethasone and RU38486 on the PNMT promoter. The wild-type construct pGL3RP790 was transfected into RS1 cells as described under Materials and Methods. The transfected cells were treated with dexamethasone (0 -10 M) or pretreated with RU38486 (0 -10 M) for 1 h, followed by 1 M dexamethasone. After 6 h, cells were collected and luciferase activity measured. A, dexamethasone responsiveness of the PNMT promoter. ***, significantly different from untreated wild-type control, p Յ 0.001. B, RU38486 effects on dexamethasoneresponsiveness of the PNMT promoter. ***, significantly different from wild-type control, p Յ 0.001. Fig. 3 . Affinity of glucocorticoid receptor for Ϫ773-and Ϫ759-bp GREs. Gel mobility shift competition assays were performed as described under Materials and Methods using a truncated glucocorticoid receptor protein and the 32 P-labeled 40-bp wild-type oligonucleotide probe GRE773/759. The protein-DNA complex was competed with 1-1000 ng of homologous, unlabeled competitor DNA (GRE773/759) or 21-bp oligonucleotides encoding the Ϫ773-bp GRE (GRE773), the Ϫ759-bp GRE (GRE759), or the palindromic GRE (palGRE) (Scheidereit et al., 1983 The effects of RU38486 on dexamethasone-stimulated PNMT promoter activation was also determined for all of the mutant constructs. As above, cells transfected with the constructs were pretreated with the antagonist (0-10 M) for 1 h followed by 6 h of 1 M dexamethasone treatment (Fig. 4B) . The construct harboring a mutation in the Ϫ533-bp GRE (pGL3RP790mut533) showed PNMT promoter-driven luciferase expression similar to that of the wild-type construct (pGL3RP790). At concentrations of 0.1 and 1 M, luciferase activity was, in fact, slightly higher than the wild-type control cells. The construct harboring a mutation in the Ϫ773-bp GRE (pGL3RP790mut773) showed a linear decrease in dexamethasone-stimulated, PNMT promoter-driven luciferase expression as would be expected based on its responses to dexamethasone described above. Similarly, the mutant construct with altered Ϫ759-bp GRE showed no significant dexamethasone and RU38486 responsiveness. Finally, when the Ϫ759-and Ϫ773-bp or the Ϫ533-, Ϫ759-, and Ϫ773-bp GREs were mutated, neither dexamethasone nor the combination of dexamethasone and RU38486 elicited any significant changes in PNMT promoter expression whatsoever.
Cooperative Interactions between the GR and Other PNMT Transcriptional Activators. Many transcriptional regulators can independently and cooperatively stimulate gene expression. Although the Ϫ533-bp GRE in the rat PNMT promoter is apparently a weak independent glucocorticoid activation site, bound GR seemed to cooperatively activate the PNMT promoter through interactions with Egr-1 and/or AP-2 bound to their respective consensus elements at Ϫ165, Ϫ674, and Ϫ587 bp . As described earlier (Fig. 1) , two deletion constructs, pGL3RP557 and pGL3RP665, which harbor the Ϫ533-bp GRE but not the Ϫ759 or Ϫ773-bp GREs, showed no significant glucocorticoid activation. However, dexamethasone did induce luciferase reporter gene expression 2.0-fold from a slightly longer construct, pGL3RP745, a construct containing functional AP-2 binding sites .
To further investigate the role of the Ϫ533-bp GRE and the possible role of the Ϫ759-and Ϫ773-bp GREs in cooperative stimulation of the PNMT promoter, transient transfection assays were executed with the wild-type and mutant PNMT promoter-luciferase reporter gene constructs in the absence or presence of 1 M dexamethasone and Egr-1 and/or AP-2 expression constructs. First, cooperativity between the GR and Egr-1 was investigated (Fig. 5A) . Although dexamethasone stimulated only a 3.0-fold rise in PNMT promoterdriven luciferase activity in this case, mutation of the Ϫ533-bp GRE increased dexamethasone stimulation of the promoter 3.8-fold beyond that observed with the wild-type construct. In contrast, mutation of the Ϫ759-bp GRE, Ϫ773-bp GRE, both the Ϫ759-and Ϫ773-bp GREs, or the Ϫ533-, Ϫ759-, and Ϫ773-bp GREs almost completely abolished the glucocorticoid responsiveness of the PNMT promoter. Egr-1 alone stimulated a 2.6-fold increase in PNMT promoter-driven luciferase expression in the wild-type PNMT promoter-luciferase construct and in combination with dexamethasone, increased promoter activity slightly more than the additive inductions by the GR and Egr-1, consistent with GR and Egr-1 acting cooperatively to induce PNMT promoter-driven transcriptional activity. However, if the Ϫ533-bp GRE was mutated, Egr-1 or Egr-1 combined with dexamethasone stimulated the PNMT promoter 2-to 4-fold more than when the site was intact (4.5 and 9.8-fold, respectively). When the Ϫ759-bp GRE, the Ϫ773-bp GRE, the Ϫ759-and Ϫ773-bp GREs, or the Ϫ533-, Ϫ759-, and Ϫ773-bp GREs were mutated, stimulation of the PNMT promoter by Egr-1 and Egr-1 in combination with dexamethasone declined precipitously. However, Egr-1-mediated, PNMT promoter induction was still significantly greater than their respective controls in the case of the Ϫ759-and Ϫ533-/Ϫ759-/Ϫ773-bp mutant constructs (5.0-and 2.0-fold, Fig. 4 . Site-directed mutagenesis of GREs and PNMT promoter responsiveness to glucocorticoids. PNMT promoter-luciferase reporter gene constructs were generated with mutations in the Ϫ773, Ϫ759, Ϫ773 and Ϫ759, Ϫ533 and all three GREs (pGL3RP790mut773, pGL3RP790mut759, pGL3RP790mut773/759, pGL3RP790mut533, and pGL3RP790mut773/759/533, respectively). The wild-type construct pGL3RP790 or mutant constructs were transfected into RS1 cells and treated with dexamethasone (0 -10 M). Alternatively, transfected cells were pretreated with RU38486 (0 -10 M) for 1 h, followed by treatment with 1 M dexamethasone for 6 h. Cell lysates were prepared and luciferase activity measured as described under Materials and Methods. A, glucocorticoid responsiveness of wild-type construct pGL3RP790 and mutant constructs pGL3RP790mut773, pGL3RP790mut759, and pGL3Rpmut773/759 in RS1 cells. c, significantly different from wild-type control, p Յ 0.001. B, effects of RU38486 on the glucocorticoid responsiveness of wild-type pGL3RP790 and mutant constructs, pGL3RP790mut533, pGL3RP790mut773/759, and pGL3RP790mut773/ 759/533 in RS1 cells. a, significantly different from dexamethasonetreated wild-type control, p Յ 0.05; b, significantly different from dexamethasone-treated wild-type control, p Յ 0.01; c, significantly different from dexamethasone-treated wild-type control, p Յ 0.001.
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at ASPET Journals on June 15, 2017 molpharm.aspetjournals.org respectively). It was previously demonstrated that AP-2 induction of the PNMT promoter required coactivation of the GR . In the present study, AP-2 seems to independently stimulate PNMT promoter-driven luciferase activity in the case of the wild-type construct (3.7-fold), but synergistic activation by AP-2 and dexamethasone still occurred (20.7-fold). When the Ϫ533-or Ϫ773-bp GREs were mutated, similar responses were observed, although induction was markedly attenuated. However, if the Ϫ759-bp, Ϫ759-and Ϫ773-bp, or Ϫ533-, Ϫ759-, and Ϫ773-bp GREs were mutated, both the independent AP-2 and GR and AP-2 synergistic stimulation of the PNMT promoter was eliminated.
As reported earlier , greatest synergistic activation of the PNMT promoter was elicited in the presence of all three transcriptional activators, the GR, AP-2, and Egr-1 (ϳ28.0-fold). Moreover, mutation of the Ϫ533-bp GRE increased PNMT promoter activity 4.0-fold beyond that observed with the wild-type construct (91.5-fold). In contrast, mutation of either the Ϫ759 or Ϫ773-bp GREs markedly attenuated synergistic stimulation of the promoter (25% of wild-type) although a significant 6.0-to 7.9-fold activation remained. Finally, when both the Ϫ759-and Ϫ773-bp GREs as well as all three GREs were mutated, cooperative interactions were completely lost.
Discussion
Glucocorticoids are important regulators of PNMT gene expression, influencing adrenergic differentiation (Bohn et al., 1981; Teitelman et al., 1982; Bohn, 1983; Michelson and Anderson, 1992; Wong et al., 1992a; Schmid et al., 1995; Ebert et al., 1997) and the induction of PNMT in response to acute and chronic stress (Sabban et al., 1995; Sabban et al., 1998; Serova et al., 1998) . Consistent with this role, a functional GRE was identified at Ϫ513 bp in the upstream sequences of the rat PNMT gene when it was first cloned (Ross et al., 1990) . At best, however, only weak glucocorticoid responses are elicited through this GRE based on changes in PNMT promoter-reporter gene expression and PNMT mRNA expression in vitro Ebert et al., 1997) . Two additional glucocorticoid response elements have now been identified distal to the original GRE. These GREs, located at Ϫ759 and Ϫ773 bp upstream of the site of transcription initiation, overlap by 1 bp according to the consensus sequence defined by Scheidereit et al. (1983) and together contribute to a maximum 12.0-fold induction of the PNMT promoter in response to glucocorticoids.
The position of these new GREs has been designated by their 3Ј termini based on the highly conserved 3Ј-hexanucleotide sequence TGTTCT in the 15-bp palindromic GRE, 5ЈAGAACANNNTCTTCT3Ј identified above. These designations also correct for misalignment of the proximal PNMT promoter sequences arising from ϳ30 bp of G and C residues in GC rich regions where sequencing is difficult. Realignment of the promoter repositions the Ϫ513-bp GRE at Ϫ533 bp as well.
The relative contribution of each new GRE to the corticosteroid responsiveness of the PNMT promoter was investigated by site-directed mutagenesis, gel mobility shift competition assays, and examination of the effects of dexamethasone and the antiglucocorticoid RU38486. Both GREs must be intact to elicit full glucocorticoid sensitivity of the PNMT promoter, and the response seems greater than additive, indicating cooperativity between activated GRs bound to the GREs or bound GRs and other transcription factors. In addition, the Ϫ759-bp GRE has ϳ2-fold higher affinity for the GR, which was reflected by a greater attenuation of glucocorticoidstimulated PNMT promoter activity when this GRE was mutated. Thus, this GRE is probably functionally more important. Finally, RU38486 effectively blocked glucocorticoid activation from either response element in a dose-dependent manner, consistent with the relative affinities of the GR for each GRE. The latter results also confirm that glucocorticoid activation of the PNMT gene promoter occurs through type II GRs because RU38486 is a classic GR antagonist.
In keeping with previous reports, the Ϫ533-bp GRE did not seem to markedly affect PNMT promoter activation through glucocorticoid exposure alone. Two PNMT promoter constructs (pGL3RP665 and pGL3RP557) containing this GRE, but not the Ϫ773-and Ϫ759-bp upstream GREs, failed to Cooperative stimulation of the PNMT promoter by the glucocorticoid receptor and Egr-1 and/or AP2. RS1 cells were transfected with the wild-type construct pGL3RP790 or cotransfected with the wild-type construct and expression constructs for Egr-1, pCMVEgr-1, and AP-2, pSPRSV-AP-2, as described under Materials and Methods. The cells were sustained in the absence or presence of 1 M dexamethasone for 6 h, after which luciferase activity was measured. a, significantly different from dexamethasone-treated wild-type control, p Յ 0.05; b, significantly different from dexamethasone-treated wild-type control, p Յ 0.01; c, significantly different from dexamethasone-treated wild-type control, p Յ 0.001. show an increase in PNMT promoter activity when treated with corticosteroids. However, a 2-fold induction of the luciferase reporter gene was observed with a slightly longer construct pGL3RP745. The latter also harbors two functional AP-2 binding elements at Ϫ674 and Ϫ587 bp . In contrast to our earlier results, the present findings suggest that AP-2 alone can elicit a significant, but limited induction of the PNMT promoter. Most notable again is the marked cooperative induction of the promoter by GR bound to the Ϫ533-bp GRE and AP-2. AP-2 and dexamethasone synergism is demonstrated by the nearly 2.0-fold reduction (relative to wild-type) in PNMT promoter-driven luciferase activity when the Ϫ533-bp GRE is mutated. Curiously, when the Ϫ759-and Ϫ773-bp GREs are mutated and the Ϫ533-bp GRE left intact, synergism disappears. It may be that binding of GRs to these GREs alters PNMT promoter conformation in a fashion that favors the interaction between GRs bound to the Ϫ533-bp GRE and AP-2. Alternatively, GR bound to the Ϫ533, Ϫ759, and Ϫ773-bp GREs may interact with one another and/or AP-2. Whereas the Ϫ533-bp GRE participates in AP-2 and GR cooperative activation of the PNMT promoter, synergism between bound GR and the immediate early gene transcription factor Egr-1 does not occur, because there is no significant difference in their combined effects on PNMT promoter activity when this site is mutated. The latter results further suggested that previously reported cooperative induction by Egr-1 and dexamethasone might involve the newly identified tandem GREs. When the Ϫ533-bp GRE is mutated, leaving only these two GREs intact, Egr-1 and dexamethasone elicit a 5.0-fold higher stimulation of the PNMT promoter than observed with the wildtype construct where all three GRE sites are intact. Moreover, when these GREs are mutated independently, together or along with the Ϫ533-bp GRE, activation by Egr-1 and dexamethasone is effectively eliminated. Thus, the Ϫ759-and Ϫ773-bp GREs do seem to be the essential GREs for cooperative activation of the PNMT promoter by Egr-1 and the GR. In addition, the Ϫ759-and Ϫ773-bp GREs also participate in synergistic activation of the PNMT promoter with AP-2, although their contribution to GR and AP-2 activation of the promoter is less than that orchestrated through the Ϫ533-bp GRE. When the Ϫ533-bp GRE is mutated, AP-2 still elicited a residual ϳ12.0-fold stimulation of PNMT promoter-driven luciferase expression. Finally, these independent synergistic effects are reflected in the combined effects of AP-2, Egr-1, and the GR on the wild-type and mutant constructs.
Clearly, these cooperative interactions are complex and very dependent on promoter length, acetylated histones, and DNA folding and interaction as well as the availability of coactivator complexes containing factors such as SCRC1, GRIP1, CBP, P300, and PCAF (Wang et al., 1999) . Current studies are now investigating the effects of selective silencing of the GREs, Egr-1 and AP-2 binding elements in PNMT promoter constructs and endogenous PNMT gene using viral vector driven antisense strategies.
In summary, the present study provides the first definitive identification and characterization of the functional GREs in the proximal sequences in the rat PNMT promoter. Through the newly identified Ϫ759-and Ϫ773-bp GREs, marked and selective glucocorticoid activation occurs, indicating that they are the primary targets through which glucocorticoid sensitivity is conferred. In addition, both the Ϫ533-bp GRE and these newly identified GREs seem to participate in cooperative or facilitatory activation of the PNMT promoter, the former with AP-2 and the latter with AP-2, Egr-1, and/or both.
